Clinical

Dataset Information

0

Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G)

ABSTRACT: Primary outcome(s): Overall survival

DISEASE(S): Braf V600e-mutant Metastatic Colorectal Cancer

PROVIDER: 2655825 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
| S-EPMC4993103 | biostudies-literature
Unknown Combined BRAF<sup>V600E</sup> and MEK blockade for BRAF<sup>V600E</sup>-mutant gliomas.
| S-EPMC5560871 | biostudies-literature
Unknown Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report.
| S-EPMC6765470 | biostudies-literature
Unknown Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
| S-EPMC6291325 | biostudies-literature
Unknown Management of V600E and V600K BRAF-Mutant Melanoma.
| S-EPMC10176035 | biostudies-literature
Unknown Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.
| S-EPMC11537293 | biostudies-literature
Unknown Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
| S-EPMC4907264 | biostudies-literature
Unknown Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
| S-EPMC8078423 | biostudies-literature
Unknown Functional characterization of a PROTAC directed against BRAF mutant V600E.
| S-EPMC7862923 | biostudies-literature
Unknown Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1.
| S-EPMC5542387 | biostudies-literature